Lumius

Competitive Intelligence & Product Roadmap

Real-time 3D ultrasound for vascular access and procedure guidance.

Company Overview

Lumius is a medical imaging device company that turns ultrasound into real-time 3D volumes using Diffractive Acoustic Tomography. Serving clinicians in vascular access and procedure guidance; public customers are not disclosed.

Latest Intel

Zeitgeist tracks private signals to determine where the company is heading strategically.

New Intel: Lumius is centering Diffractive Acoustic Tomography on vascular access. If low-cost 3D ultrasound works, Butterfly, Clarius, Philips Lumify, and Fujifilm Sonosite face pressure in guided procedure workflows.

What They're Building

The company's public product roadmap & what they're committed to building.

Plugin Module

A plug-in 3D ultrasound module is presented as the near-term path to add real-time volume imaging to clinical workflows.

Full Probe

The full probe extends the same DAT approach into a compact dedicated device for portable 3D imaging.

Vascular Access

Central line placement is the first stated use case, where a 3D view can reduce the mental reconstruction required by 2D ultrasound.

AI Guidance

Lumius describes AI assistance that can identify anatomy such as vessels, nerves, and muscle, then guide the user through what they see.

Broader Procedure Imaging

Future stated uses include blood clot detection, nerve block imaging, tumor diagnosis, and biopsy guidance.

Founder and Key Execs

Tri Vu

Co-Founder & CEO (Duke BME PhD)

Luca Menozzi

Co-Founder & CTO (Duke PhD in ultrasound and photoacoustic imaging)

Chenhang Li

Co-Founder & CFO/COO (Duke PhD with wearable electronics work)

Junjie Yao

Scientific Advisor & Co-Founder (Duke professor and DAT research lead)

Founder Force Multiplier

Tri Vu, Luca Menozzi, and Chenhang Li bring Duke BME, ultrasound, photoacoustic imaging, and wearable electronics work to a device whose core risk is physics plus productization. Junjie Yao adds direct continuity from the underlying DAT research.

Funding History

2025 | NC Biotechnology Center Industrial Internship Program support for prototype development
2025 | Duke-Coulter Translational Partnership award for clinical development and commercialization of DAT
2026 | Accepted into Y Combinator Spring 2026

Competitors

Butterfly Network:

Butterfly sells handheld ultrasound systems, while Lumius is aiming at low-cost real-time 3D volume imaging rather than conventional 2D scanning.

Fujifilm Sonosite:

Sonosite has established point-of-care ultrasound distribution and AI vascular access tools, while Lumius is betting on a different 3D imaging layer.

Philips Lumify:

Lumify is a mobile ultrasound product line for 2D imaging, while Lumius' public claim centers on compact 3D ultrasound.

Clarius:

Clarius competes in handheld ultrasound, while Lumius' stated edge is DAT-based real-time 3D imaging and guided procedures.

Lumius

's Moat:

The candidate moat is technical infrastructure: DAT hardware plus reconstruction IP could be hard to copy, but clinical data and regulatory proof still need to compound.

How They're Leveraging AI

Volumetric anatomy recognition

Lumius describes AI assistance that identifies anatomy such as vessels, nerves, and muscle inside a real-time 3D ultrasound view. The user is the clinician performing vascular access or another guided procedure.

DAT-guided 3D reconstruction

Lumius' core imaging system appears to convert raw ultrasound or photoacoustic signals into real-time 3D volumes using Diffractive Acoustic Tomography. The ML-adjacent value is in computational reconstruction fast enough for procedure guidance.

Procedure guidance from live ultrasound

Lumius points toward an AI assistant that explains what clinicians are seeing and what to do next during vascular access and later procedures. This would turn image interpretation into stepwise clinical guidance.

AI Use Overview:

Lumius' ML edge is likely volumetric anatomy segmentation layered on DAT reconstruction, where the hard problem is guiding procedures from a real-time 3D ultrasound volume.

Bio, Drug Discovery, and Medical Imaging

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Mango Medical

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.

Back To All Companies >